Pair your accounts.

Export articles to Mendeley

Get article recommendations from ACS based on references in your Mendeley library.

Pair your accounts.

Export articles to Mendeley

Get article recommendations from ACS based on references in your Mendeley library.

You’ve supercharged your research process with ACS and Mendeley!

Click to create an ACS ID

Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.

Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.

Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.

Your Mendeley pairing has expired. Please reconnect
ACS Publications. Most Trusted. Most Cited. Most Read
My Activity

The Discovery of Sulfonamide Endothelin Antagonists and the Development of the Orally Active ETA Antagonist 5-(Dimethylamino)-N-(3,4-dimethyl-5- isoxazolyl)-1-naphthalenesulfonamide

Cite this: J. Med. Chem. 1994, 37, 3, 329–331
Publication Date (Print):February 1, 1994
    ACS Legacy Archive

    Article Views





    Other access options
    Supporting Info (1)»

    Note: In lieu of an abstract, this is the article's first page.

    Free first page

    Read this article

    To access this article, please review the available access options below.

    Get instant access

    Purchase Access

    Read this article for 48 hours. Check out below using your ACS ID or as a guest.


    Access through Your Institution

    You may have access to this article through your institution.

    Your institution does not have access to this content. You can change your affiliated institution below.

    Supporting Information

    Terms & Conditions

    Electronic Supporting Information files are available without a subscription to ACS Web Editions. The American Chemical Society holds a copyright ownership interest in any copyrightable Supporting Information. Files available from the ACS website may be downloaded for personal use only. Users are not otherwise permitted to reproduce, republish, redistribute, or sell any Supporting Information from the ACS website, either in whole or in part, in either machine-readable form or any other form without permission from the American Chemical Society. For permission to reproduce, republish and redistribute this material, requesters must process their own requests via the RightsLink permission system. Information about how to use the RightsLink permission system can be found at

    Cited By

    This article is cited by 125 publications.

    1. Joanna Wojnarska, Marlena Gryl, Tomasz Seidler, Katarzyna M. Stadnicka. Effect of Substituent Exchange on Optical Anisotropy in Multicomponent Isostructural Materials Containing Sulfathiazole and 2-Aminopyridine Derivatives. Crystal Growth & Design 2020, 20 (10) , 6535-6544.
    2. Eliezer J. Barreiro, Arthur E. Kümmerle, and Carlos A. M. Fraga . The Methylation Effect in Medicinal Chemistry. Chemical Reviews 2011, 111 (9) , 5215-5246.
    3. Jade S. Blakeney,, Robert C. Reid,, Giang T. Le, and, David P. Fairlie. Nonpeptidic Ligands for Peptide-Activated G Protein-Coupled Receptors. Chemical Reviews 2007, 107 (7) , 2960-3041.
    4. Camille G. Wermuth. Selective Optimization of Side Activities:  Another Way for Drug Discovery. Journal of Medicinal Chemistry 2004, 47 (6) , 1303-1314.
    5. Natsuki Ishizuka,, Ken-ichi Matsumura,, Katsunori Sakai,, Masafumi Fujimoto,, Shin-ichi Mihara, and, Teruo Yamamori. Structure−Activity Relationships of a Novel Class of Endothelin-A Receptor Antagonists and Discovery of Potent and Selective Receptor Antagonist, 2-(Benzo[1,3]dioxol-5-yl)-6-isopropyloxy-4-(4-methoxyphenyl)-2H-chromene-3- carboxylic Acid (S-1255). 1. Study on Structure−Activity Relationships and Basic Structure Crucial for ETA Antagonism. Journal of Medicinal Chemistry 2002, 45 (10) , 2041-2055.
    6. Natesan Murugesan,, Zhengxiang Gu,, Philip D. Stein,, Steven Spergel,, Arvind Mathur,, Leslie Leith,, Eddie C.-K. Liu,, Rongan Zhang,, Eileen Bird,, Tom Waldron,, Anthony Marino,, Richard A. Morrison,, Maria L. Webb,, Suzanne Moreland, and, Joel C. Barrish. Biphenylsulfonamide Endothelin Receptor Antagonists. 2. Discovery of 4‘-Oxazolyl Biphenylsulfonamides as a New Class of Potent, Highly Selective ETA Antagonists. Journal of Medicinal Chemistry 2000, 43 (16) , 3111-3117.
    7. Chengde Wu,, E. Radford Decker,, Natalie Blok,, Huong Bui,, Qi Chen,, B. Raju,, Andree R. Bourgoyne,, Vippra Knowles,, Ronald J. Biediger,, Robert V. Market,, Shuqun Lin,, Brian Dupré,, Timothy P. Kogan,, George W. Holland,, Tommy A. Brock, and, Richard A. F. Dixon. Endothelin Antagonists:  Substituted Mesitylcarboxamides with High Potency and Selectivity for ETA Receptors. Journal of Medicinal Chemistry 1999, 42 (22) , 4485-4499.
    8. Natesan Murugesan,, Zhengxiang Gu,, Philip D. Stein,, Sharon Bisaha,, Steve Spergel,, Ravi Girotra,, Ving G. Lee,, John Lloyd,, Raj N. Misra,, Joan Schmidt,, Arvind Mathur,, Leslie Stratton,, Yolanda F. Kelly,, Eileen Bird,, Tom Waldron,, Eddie C.-K. Liu,, Rongan Zhang,, Helen Lee,, Randy Serafino,, Benoni Abboa-Offei,, Parker Mathers,, Mary Giancarli,, Andrea Ann Seymour,, Maria L. Webb,, Suzanne Moreland,, Joel C. Barrish, and, John T. Hunt. Biphenylsulfonamide Endothelin Antagonists:  Structure−Activity Relationships of a Series of Mono- and Disubstituted Analogues and Pharmacology of the Orally Active Endothelin Antagonist 2‘-Amino-N- (3,4-dimethyl-5-isoxazolyl)-4‘-(2-methylpropyl)[1,1‘-biphenyl]-2-sulfonamide (BMS-187308). Journal of Medicinal Chemistry 1998, 41 (26) , 5198-5218.
    9. Gang Liu,, Kenneth J. Henry, Jr.,, Bruce G. Szczepankiewicz,, Martin Winn,, Natasha S. Kozmina,, Steven A. Boyd,, James Wasicak,, Thomas W. von Geldern,, Jinshyun R. Wu-Wong,, William J. Chiou,, Douglas B. Dixon,, Bach Nguyen,, Kennan C. Marsh, and, Terry J. Opgenorth. Pyrrolidine-3-carboxylic Acids as Endothelin Antagonists. 3. Discovery of a Potent, 2-Nonaryl, Highly Selective ETA Antagonist (A-216546). Journal of Medicinal Chemistry 1998, 41 (17) , 3261-3275.
    10. Peter C. Astles,, Thomas J. Brown,, Frank Halley,, Caroline M. Handscombe,, Neil V. Harris,, Clive McCarthy,, Iain M. McLay,, Peter Lockey,, Tahir Majid,, Barry Porter,, Alan G. Roach,, Christopher Smith, and, Roger Walsh. Selective Endothelin A Receptor Antagonists. 4. Discovery and Structure−Activity Relationships of Stilbene Acid and Alcohol Derivatives. Journal of Medicinal Chemistry 1998, 41 (15) , 2745-2753.
    11. Chengde Wu,, Ming F. Chan,, Fiona Stavros,, B. Raju,, Ilya Okun, and, Rosario S. Castillo. Structure−Activity Relationships of N 2-Aryl-3-(isoxazolylsulfamoyl)-2-thiophenecarboxamides as Selective Endothelin Receptor-A Antagonists. Journal of Medicinal Chemistry 1997, 40 (11) , 1682-1689.
    12. Robert H. Bradbury,, Colin Bath,, Roger J. Butlin,, Michael Dennis,, Christine Heys,, Sarah J. Hunt,, Roger James,, Andrew A. Mortlock,, Neil F. Sumner,, Eric K. Tang,, Berwick Telford,, Elaine Whiting, and, Campbell Wilson. New Non-Peptide Endothelin-A Receptor Antagonists:  Synthesis, Biological Properties, and Structure−Activity Relationships of 5-(Dimethylamino)-N-pyridyl-, -N-pyrimidinyl-, -N-pyridazinyl-, and -N-pyrazinyl-1-naphthalenesulfonamides. Journal of Medicinal Chemistry 1997, 40 (6) , 996-1004.
    13. William C. Patt,, Jeremy J. Edmunds,, Joseph T. Repine,, Kent A. Berryman,, Billy R. Reisdorph,, Chet Lee,, Mark S. Plummer,, Aurash Shahripour,, Stephen J. Haleen,, Joan A. Keiser,, Mike A. Flynn,, Kathleen M. Welch,, Elwood E. Reynolds,, Ron Rubin,, Brian Tobias,, Hussein Hallak, and, Annette M. Doherty. Structure−Activity Relationships in a Series of Orally Active γ-Hydroxy Butenolide Endothelin Antagonists. Journal of Medicinal Chemistry 1997, 40 (7) , 1063-1074.
    14. Andrew S. Tasker,, Bryan K. Sorensen,, Hwan-Soo Jae,, Martin Winn,, Thomas W. von Geldern,, Douglas B. Dixon,, William J. Chiou,, Brian D. Dayton,, Samuel Calzadila,, Lisa Hernandez,, Kennan C. Marsh,, J. Ruth WuWong, and, Terry J. Opgenorth. Potent and Selective Non-Benzodioxole-Containing Endothelin-A Receptor Antagonists. Journal of Medicinal Chemistry 1997, 40 (3) , 322-330.
    15. Maria L. Webb,, Pramathesh S. Patel,, Patricia M. Rose,, Eddie C. K. Liu,, Philip D. Stein,, Joel Barrish,, David A. Lach,, Terry Stouch,, Susan M. Fisher,, Ophelia Hadjilambris,, Helen Lee,, Stephen Skwish,, Kenneth E. J. Dickinson, and, Stanley R. Krystek, Jr.. Mutational Analysis of the Endothelin Type A Receptor (ETA):  Interactions and Model of the Selective ETA Antagonist BMS-182874 with the Putative ETA Receptor Binding Cavity. Biochemistry 1996, 35 (8) , 2548-2556.
    16. Martin Winn,, Thomas W. von Geldern,, Terry J. Opgenorth,, Hwan-Soo Jae,, Andrew S. Tasker,, Steven A. Boyd,, Jeffrey A. Kester,, Robert A. Mantei,, Radhika Bal,, Bryan K. Sorensen,, Jinshyun R. Wu-Wong,, William J. Chiou,, Douglas B. Dixon,, Eugene I. Novosad,, Lisa Hernandez, and, Kennan C. Marsh. 2,4-Diarylpyrrolidine-3-carboxylic AcidsPotent ETA Selective Endothelin Receptor Antagonists. 1. Discovery of A-127722. Journal of Medicinal Chemistry 1996, 39 (5) , 1039-1048.
    17. Thomas W. von Geldern,, Charles Hutchins,, Jeffrey A. Kester,, Jinshyun R. Wu-Wong,, William Chiou,, Douglas B. Dixon, and, Terry J. Opgenorth. Azole Endothelin Antagonists. 1. A Receptor Model Explains an Unusual Structure−Activity Profile. Journal of Medicinal Chemistry 1996, 39 (4) , 957-967.
    18. Hartmut Riechers,, Hans-Peter Albrecht,, Willi Amberg,, Ernst Baumann,, Harald Bernard,, Hans-Joachim Böhm,, Dagmar Klinge,, Andreas Kling,, Stefan Müller,, Manfred Raschack,, Liliane Unger,, Nigel Walker, and, Wolfgang Wernet. Discovery and Optimization of a Novel Class of Orally Active Nonpeptidic Endothelin-A Receptor Antagonists. Journal of Medicinal Chemistry 1996, 39 (11) , 2123-2128.
    19. Jonathan A. Lee, Joyce A. Brinkmann, Enrique D. Longton, Catherine E. Peishoff, M. Amparo Lago, Jack D. Leber, Russell D. Cousins, Aiming Gao, Jeffrey M. Stadel, and . Lysine 182 of Endothelin B Receptor Modulates Agonist Selectivity and Antagonist Affinity: Evidence for the Overlap of Peptide and Non-peptide Ligand Binding Sites. Biochemistry 1994, 33 (48) , 14543-14549.
    20. Mohit Saroha, Jitender M. Khurana. Acetic acid mediated regioselective synthesis of 2,4,5-trisubstituted thiazoles by a domino multicomponent reaction. New Journal of Chemistry 2019, 43 (22) , 8644-8650.
    21. Sushobhan Mukhopadhyay, Dinesh S. Barak, Ilesha Avasthi, Sanjay Batra. Efficient Transformation of Alkyl 3‐nitro‐5‐(aryl/alkyl)isoxazole‐4‐carboxylates into 3‐amino‐ and 3‐hydrazinyl‐5‐aryl/alkyl‐isoxazole‐4‐carboxylates in Aqueous Solution. Advanced Synthesis & Catalysis 2017, 359 (22) , 4050-4056.
    22. M.H. Bolli, C. Boss, J. Gatfield, M. Iglarz, A. Treiber. The Discovery of Macitentan—A Standard Medicinal Chemistry Program?. 2017, 252-283.
    23. Norbert Handler, Andrea Wolkerstorfer, Helmut Buschmann. Selective Optimization of Side Activities: An Alternative and Promising Strategy for Lead Generation. 2016, 221-258.
    24. Jennifer M Sasser, Sydney R Murphy, Joey P Granger. Emerging drugs for preeclampsia – the endothelium as a target. Expert Opinion on Emerging Drugs 2015, 20 (4) , 527-530.
    25. Abdul Rouf, Cihangir Tanyeli. Bioactive thiazole and benzothiazole derivatives. European Journal of Medicinal Chemistry 2015, 97 , 911-927.
    26. Camille G. Wermuth, Bruno Villoutreix, Serge Grisoni, Anne Olivier, Jean-Philippe Rocher. Strategies in the Search for New Lead Compounds or Original Working Hypotheses. 2015, 73-99.
    27. Manish S. Lavhale, Seema Briyal, Niket Parikh, Anil Gulati. Endothelin modulates the cardiovascular effects of clonidine in the rat. Pharmacological Research 2010, 62 (6) , 489-499.
    28. Cang-Bao Xu, Yang Sun, Lars Edvinsson. Cardiovascular risk factors regulate the expression of vascular endothelin receptors. Pharmacology & Therapeutics 2010, 127 (2) , 148-155.
    29. Juan J. Perez, Francesc J. Corcho, Jaime Rubio‐Martinez. Design of Peptidomimetics. 2010, 205-248.
    30. Camille G. Wermuth. Strategies in the Search for New Lead Compounds or Original Working Hypotheses. 2008, 123-143.
    31. John R. Proudfoot. High-Throughput Screening and Drug Discovery. 2008, 144-158.
    32. Takashi Nishikata, Yasunori Yamamoto, Norio Miyaura. Palladium(II)‐Catalyzed 1,4‐Addition of Arylboronic Acids to β‐Arylenones for Enantioselective Synthesis of 4‐Aryl‐4 H ‐chromenes. Advanced Synthesis & Catalysis 2007, 349 (10) , 1759-1764.
    33. Takahiro Itoh, Toshiaki Mase, Takashi Nishikata, Tetsuji Iyama, Hiroto Tachikawa, Yuri Kobayashi, Yasunori Yamamoto, Norio Miyaura. 1,4-Addition of arylboronic acids to β-aryl-α,β-unsaturated ketones and esters catalyzed by a rhodium(I)–chiraphos complex for catalytic and enantioselective synthesis of selective endothelin A receptor antagonists. Tetrahedron 2006, 62 (41) , 9610-9621.
    34. George A. Matwyshyn, Shaifali Bhalla, Anil Gulati. Endothelin ETA receptor blockade potentiates morphine analgesia but does not affect gastrointestinal transit in mice. European Journal of Pharmacology 2006, 543 (1-3) , 48-53.
    35. Camille G. Wermuth. Selective optimization of side activities: the SOSA approach. Drug Discovery Today 2006, 11 (3-4) , 160-164.
    36. Robin R. Coombs, Melissa K. Ringer, Johanna M. Blacquiere, Joshua C. Smith, J. Scott. Neilsen, Yoon-Seo Uh, J. Bryson. Gilbert, Lisa J. Leger, Haiwen Zhang, Alison M. Irving, Susan L. Wheaton, Christopher M. Vogels, Stephen A. Westcott, Andreas Decken, Felix J. Baerlocher. Palladium(II) Schiff base complexes derived from sulfanilamides and aminobenzothiazoles. Transition Metal Chemistry 2005, 30 (4) , 411-418.
    37. Tomoh Masaki. Historical review: Endothelin. Trends in Pharmacological Sciences 2004, 25 (4) , 219-224.
    38. Hirobumi Takahashi, Norikazu Ohtake, Toshihiro Sakamoto, Tomoharu Iino, Nobuhiko Kawanishi, Masayuki Nakamura, Takashi Yoshizumi, Kenji Niiyama, Satoshi Ozaki, Hiromasa Okada, Akiko Kano, Hiroyuki Takahashi, Yasuyuki Ishii, Megumu Okada, Michiyasu Saito, Yoshio Sawazaki, Takashi Hayama, Masaru Nishikibe. Structure–activity relationships of a novel class of endothelin receptor selective antagonists; 6-carboxy-2-isopropylamino-5,7-diarylcyclopenteno[1,2-b]pyridines. Bioorganic & Medicinal Chemistry Letters 2004, 14 (6) , 1503-1507.
    39. Ghassan Bkaily, Sanaa Choufani, Sawsan Sader, Danielle Jacques, Pedro d'Orléans-Juste, Moni Nader, Ghada Kurban, Maud Kamal. Activation of sarcolemma and nuclear membranes ET-1 receptors regulates transcellular calcium levels in heart and vascular smooth muscle cells. Canadian Journal of Physiology and Pharmacology 2003, 81 (6) , 654-662.
    40. Udo E.W Lange, Wilfried M Braje, Willi Amberg, Georg Kettschau. Solid-Phase synthesis of endothelin receptor antagonists. Bioorganic & Medicinal Chemistry Letters 2003, 13 (10) , 1721-1724.
    41. Shaifali Bhalla, George Matwyshyn, Anil Gulati. Endothelin receptor antagonists restore morphine analgesia in morphine tolerant rats. Peptides 2003, 24 (4) , 553-561.
    42. John E Tellew, Rose Ann F Baska, Sophie M Beyer, Kenneth E Carlson, Lyndon A Cornelius, Leena Fadnis, Zhengxiang Gu, Bridgette L Kunst, Mark C Kowala, Hossain Monshizadegan, Natesan Murugesan, Carol S Ryan, Maria T Valentine, Yifan Yang, John E Macor. Discovery of 4′-[(Imidazol-1-yl)methyl]biphenyl-2-sulfonamides as dual endothelin/Angiotensin II receptor antagonists. Bioorganic & Medicinal Chemistry Letters 2003, 13 (6) , 1093-1096.
    43. M. Angels Estiarte, Daniel H. Rich. Peptidomimetics for Drug Design. 2003, 633-685.
    44. Saeho Chong, Mary Obermeier, W. Griffith Humphreys. Pharmacokinetics and metabolism of endothelin receptor antagonist: Contribution of kidneys in the overallin vivo N-demethylation. Archives of Pharmacal Research 2003, 26 (1) , 89-94.
    45. Kenji Niiyama, Hirobumi Takahashi, Toshio Nagase, Hisaki Kojima, Yuka Amano, Kasumi Katsuki, Takeru Yamakawa, Satoshi Ozaki, Masaki Ihara, Mitsuo Yano, Takahiro Fukuroda, Masaru Nishikibe, Kiyofumi Ishikawa. Structure–Activity relationships of 2-substituted 5,7-Diarylcyclopenteno[1,2-b]pyridine-6-carboxylic acids as a novel class of endothelin receptor antagonists. Bioorganic & Medicinal Chemistry Letters 2002, 12 (21) , 3041-3045.
    46. Shaifali Bhalla, George Matwyshyn, Anil Gulati. Potentiation of morphine analgesia by BQ123, an endothelin antagonist. Peptides 2002, 23 (10) , 1837-1845.
    47. Kenji Niiyama, Toshiaki Mase, Hirobumi Takahashi, Akira Naya, Kasumi Katsuki, Toshio Nagase, Satoshi Ito, Takashi Hayama, Akihiro Hisaka, Satoshi Ozaki, Masaki Ihara, Mitsuo Yano, Takahiro Fukuroda, Kazuhito Noguchi, Masaru Nishikibe, Kiyofumi Ishikawa. 6-Carboxy-5,7-diarylcyclopenteno[1,2-b]pyridine derivatives. Bioorganic & Medicinal Chemistry 2002, 10 (8) , 2461-2470.
    48. Bruno A. Escalante, John C. McGiff, Adebayo O. Oyekan. Role of cytochrome P -450 arachidonate metabolites in endothelin signaling in rat proximal tubule. American Journal of Physiology-Renal Physiology 2002, 282 (1) , F144-F150.
    49. Yasuhiko Kanda, Yasuyuki Kawanishi, Katsuo Oda, Teruo Sakata, Shin-ichi Mihara, Kenji Asakura, Toshiyuki Kanemasa, Mitsuyoshi Ninomiya, Masafumi Fujimoto, Toshiro Konoike. Synthesis and structure–activity relationships of potent and orally active sulfonamide ETB selective antagonists. Bioorganic & Medicinal Chemistry 2001, 9 (4) , 897-907.
    50. S. A. Douglas, E. H. Ohlstein. Vascular and Cardiac Effects of Endothelin. 2001, 405-451.
    51. P. J. Henry, R. G. Goldie. Endothelin Receptors. 2001, 69-114.
    52. J. D. Elliott, J.-N. Xiang. Endothelin Receptor Antagonists. 2001, 239-270.
    53. Jidong Zhang, Stanislas Didierlaurent, Michel Fortin, Dominique Lefrançois, Eric Uridat, Jean Paul Vevert. Potent nonpeptide endothelin antagonists. Bioorganic & Medicinal Chemistry Letters 2000, 10 (22) , 2575-2578.
    54. Yasuhiko Kanda, Tadashi Takahashi, Yoshitaka Araki, Toshiro Konoike, Shin-ichi Mihara, Masafumi Fujimoto. Discovery and synthesis of a potent sulfonamide ETB selective antagonist. Bioorganic & Medicinal Chemistry Letters 2000, 10 (16) , 1875-1878.
    55. Jean-Luc Haesslein, Isabelle Baholet, Michel Fortin, Alain Iltis, Jean Khider, Anne Marie Periers, Christine Pierre, Jean-Paul Vevert. 1,3-Disubstituted-2-carboxy quinolones: highly potent and selective endothelin A receptor antagonists. Bioorganic & Medicinal Chemistry Letters 2000, 10 (13) , 1487-1490.
    56. Francisca Lopes, Rui Moreira, Jim Iley. Acyloxymethyl as a drug protecting group. Part 6. Bioorganic & Medicinal Chemistry 2000, 8 (4) , 707-716.
    57. Simon J. Teague, Andrew M. Davis, Paul D. Leeson, Tudor Oprea. Design kombinatorischer Leitstruktur-Bibliotheken. Angewandte Chemie 1999, 111 (24) , 3962-3967.<3962::AID-ANGE3962>3.0.CO;2-8
    58. Pietro Amedeo Modesti, Simone Vanni, Rita Paniccia, Brunella Bandinelli, Iacopo Bertolozzi, Gianluca Polidori, Guido Sani, Gian Gastone Neri Serneri. Characterization of Endothelin-1 Receptor Subtypes in Isolated Human Cardiomyocytes. Journal of Cardiovascular Pharmacology 1999, 34 (3) , 333-339.
    59. Pietro Amedeo Modesti, Simone Vanni, Rita Paniccia, Avio Perna, Massimo Maccherini, Gianfranco Lisi, Guido Sani, Gian Gastone Neri Serneri. Endothelin receptors in adult human and swine isolated ventricular cardiomyocytes. Biochemical Pharmacology 1999, 58 (2) , 369-374.
    60. Timothy D. Warner. Endothelin Receptors and Ligands. 1999, 21-48.
    61. Ming Fai Chan, Adam Kois, Erik J. Verner, Bore G. Raju, Rosario S. Castillo, Chengde Wu, Ilya Okun, Fiona D. Stavros, V.N. Balaji. The discovery and structure—activity relationships of nonpeptide, low molecular weight antagonists selective for the endothelin ETB receptor. Bioorganic & Medicinal Chemistry 1998, 6 (12) , 2301-2316.
    62. Adebayo O. Oyekan, J. C. McGiff. Functional response of the rat kidney to inhibition of nitric oxide synthesis: role of cytochrome P450‐derived arachidonate metabolites. British Journal of Pharmacology 1998, 125 (5) , 1065-1073.
    63. K.A. Berryman, J.J. Edmunds, A.M. Bunker, S. Haleen, J. Bryant, K.M. Welch, A.M. Doherty. Endothelin receptor antagonists: synthesis and structure–activity relationships of substituted benzothiazine-1,1-dioxides. Bioorganic & Medicinal Chemistry 1998, 6 (9) , 1447-1456.
    64. Peter Cernacek, Luigi Franchi, Jocelyn Dupuis, Jean-Lucien Rouleau, Mortimer Levy. Radioreceptor assay of an endothelin A receptor antagonist in plasma and urine. Clinical Chemistry 1998, 44 (8) , 1666-1673.
    65. Anna P Piovezan, Pedro D'Orléans-Juste, Carlos R Tonussi, Giles A Rae. Effects of endothelin-1 on capsaicin-induced nociception in mice. European Journal of Pharmacology 1998, 351 (1) , 15-22.
    66. Thomas Subkowski, Heinz Hillen, Burkhard Kröger, Martin Schmidt. Monoclonal Antibodies Against Human Endothelin-Converting Enzyme-1. Journal of Immunoassay 1998, 19 (2-3) , 75-93.
    67. Kirsty M. McCulloch, Cheryl Docherty, Margaret R. MacLean. Endothelin receptors mediating contraction of rat and human pulmonary resistance arteries: effect of chronic hypoxia in the rat. British Journal of Pharmacology 1998, 123 (8) , 1621-1630.
    68. Jonathan A. Lee, Eliot H. Ohlstein, Catherine E. Peishoff, John D. Elliott. Molecular Biology of the Endothelin Receptors. 1998, 31-73.
    69. Timothy D. Warner. The Development of Specific Endothelin-Receptor Antagonists. 1998, 189-222.
    70. Andrew S. Tasker, David M. Pollock. Endothelin Receptors and Receptor Antagonists. 1998, 3-15.
    71. Werner W.K.R Mederski, Mathias Osswald, Dieter Dorsch, Soheila Anzali, Maria Christadler, Claus-Jochen Schmitges, Claudia Wilm. 2.Endothelin antagonists: Evaluation of 2,1,3-benzothiadiazole as a methylendioxyphenyl bioisoster. Bioorganic & Medicinal Chemistry Letters 1998, 8 (1) , 17-22.
    72. Ming Yu, Venkat Gopalakrishnan, J. Robert McNeill. Hemodynamic Effects of a Selective Endothelin-A Receptor Antagonist in Deoxycorticosterone Acetate-Salt Hypertensive Rats. Journal of Cardiovascular Pharmacology 1998, 31 , S262-S264.
    73. B. Raju, Chengde Wu, Rosario Castillo, Ilya Okun, Fiona Stavros, Ming Fai Chan. 2-Aryloxycarbonylthiophene-3-sulfonamides: Highly potent and etA selective endothelin receptor antagonists. Bioorganic & Medicinal Chemistry Letters 1997, 7 (16) , 2093-2098.
    74. Andrew A. Mortlock, Colin Bath, Roger J. Butlin, Christine Heys, Sarah J. Hunt, Alan C. Reid, Neil F. Sumner, Eric K. Tang, Elaine Whiting, Campbell Wilson, Nicola D. Wright. N-Methyl-2-[4-(2-methylpropyl)phenyl]-3-(3-methoxy-5-methylpyrazin-2-ylsulfamoyl)benzamide; one of a class of novel benzenesulphonamides which are orally-active, ETA-selective endothelin antagonists. Bioorganic & Medicinal Chemistry Letters 1997, 7 (11) , 1399-1402.
    75. PC Astles, TJ Brown, CM Handscombe, MF Harper, NV Harris, RA Lewis, PM Lockey, C McCarthy, IM McLay, B Porter, AG Roach, C Smith, RJA Walsh. Selective endothelin A receptor ligands. 1. Discovery and structure-activity of 2,4-disubstituted benzoic acid derivatives. European Journal of Medicinal Chemistry 1997, 32 (5) , 409-423.
    76. JS Kaltenbronn, J Quin, BR Reisdorph, S Klutchko, EE Reynolds, KM Welch, MA Flynn, AM Doherty. Benzofuran derivatives as ETA-selective, non-peptide endothelin antagonists. European Journal of Medicinal Chemistry 1997, 32 (5) , 425-431.
    77. Maria L. Webb, Thomas D. Meek. Inhibitors of endothelin. Medicinal Research Reviews 1997, 17 (1) , 17-67.<17::AID-MED2>3.0.CO;2-W
    78. D. J. Webb, G. A. Gray. Vascular Biology of the Endothelin System. 1997, 71-90.
    79. G. A. Gray, E. J. Mickley, P. E. McEwan. Endothelin Antagonists: Novel Treatments for Hypertension?. 1997, 91-107.
    80. Ashok Kumar, Shaun Morrison, Anil Gulati. Effect of ET A Receptor Antagonists on Cardiovascular Responses Induced by Centrally Administered Sarafotoxin 6b. Peptides 1997, 18 (6) , 855-864.
    81. Donald E. Kohan. Endothelins in the normal and diseased kidney. American Journal of Kidney Diseases 1997, 29 (1) , 2-26.
    82. B. Raju, Ilya Okun, Fiona Stavros, Ming Fai Chan. Search for surrogates: A study of endothelin receptor antagonist structure activity relationships. Bioorganic & Medicinal Chemistry Letters 1997, 7 (7) , 933-938.
    83. Marie‐Claude Maurice, Jean‐Philippe Gratton, Pedro D'Orléans‐Juste. Pharmacology of two novel mixed ET A /ET B receptor antagonists, BQ‐928 and 238, in the carotid and pulmonary arteries and the perfused kidney of the rabbit. British Journal of Pharmacology 1997, 120 (2) , 319-325.
    84. X.-M. Cheng, C. Lee, S. Klutchko, T. Winters, E.E. Reynolds, K.M. Welch, M.A. Flynn, A.M. Doherty. Synthesis and structure-activity relationships of 9-substituted acridines as endothelin-A receptor antagonists. Bioorganic & Medicinal Chemistry Letters 1996, 6 (24) , 2999-3002.
    85. . {BLR 2298} Enablement. Biotechnology Law Report 1996, 983-1055.
    86. Mark C Kowala. Section Review Cardiovascular & Renal: Endothelin receptors and atherosclerosis: a potential target for therapeutic intervention. Expert Opinion on Investigational Drugs 1996, 5 (11) , 1495-1508.
    87. Ming Fai Chan, B. Raju, Adam Kois, Rosario S. Castillo, Erik J. Verner, Chengde Wu, Emily Hwang, Ilya Okun, Fiona Stavros, V.N. Balaji. Halogen substitution at the isoxazole ring enhances the activity of N-(isoxazolyl)sulfonamide endothelin antagonists. Bioorganic & Medicinal Chemistry Letters 1996, 6 (20) , 2393-2398.
    88. Toshiro Konoike, Yasuhiko Kanda, Yoshitaka Araki. Directed lithiation of N-(tert-butoxycarbonyl)aminoisoxazole: synthesis of 4-substituted aminoisoxazoles. Tetrahedron Letters 1996, 37 (19) , 3339-3342.
    89. David L Williams, Kathryn L Murphy, Nancy A Nolan, Julie A O'Brien, Edward V Lis, Douglas J Pettibone, Bradley V Clineschmidt, Stephen M Krause, Daniel F Veber, Elizabeth M Naylor, Prasun K Chakravarty, Thomas F Walsh, Dale M Dhanoa, Anna Chent, Scott W Bagley, Kenneth J Fitch, William J Greenlee. Pharmacology of L-744,453, a novel nonpeptidyl endothelin antagonist. Life Sciences 1996, 58 (14) , 1149-1157.
    90. Annette M. Doherty. Design and discovery of nonpeptide endothelin antagonists. Drug Discovery Today 1996, 1 (2) , 60-70.
    91. Kim D. Janda, Hyunsoo Han. [14] Combinatorial chemistry: A liquid-phase approach. 1996, 234-247.
    92. Gillian A. Gray, David J. Webb. The endothelin system and its potential as a therapeutic target in cardiovascular disease. Pharmacology & Therapeutics 1996, 72 (2) , 109-148.
    93. Katsuya Fujita, Yasuo Matsumura, Yohko Miyazaki, Masanori Takaoka, Shiro Morimoto. Effects of the Endothelin ETA-Receptor Antagonist FR139317 on Development of Hypertension and Cardiovascular Hypertrophy in Deoxycorticosterone Acetate-Salt Hypertensive Rats. Japanese Journal of Pharmacology 1996, 70 (4) , 313-320.
    94. Nicholas J. Lodge, Rongan Zhang, Nelly N. Halaka, Suzanne Moreland. Functional role of endothelin ETA and ETB receptors in venous and arterial smooth muscle. European Journal of Pharmacology 1995, 287 (3) , 279-285.
    95. J. Eileen Bird, Maria L. Webb, Mary R. Giancarli, Chia-Ching Chao, Charles R. Dorso, Magdi M. Asaad. A role for endothelin ETa receptors in regulation of renal function in spontaneously hypertensive rats. European Journal of Pharmacology 1995, 294 (1) , 183-189.
    96. Olivier Valdenaire, Elisabeth Rohrbacher, Marie-Geneviève Mattei. Organization of the Gene Encoding the Human Endothelin-converting Enzyme (ECE-1). Journal of Biological Chemistry 1995, 270 (50) , 29794-29798.
    97. Katsuya Fujita, Yasuo Matsumura, Yohko Miyazaki, Norio Hashimoto, Masanori Takaoka, Shiro Morimoto. ETA receptor-mediated role of endothelin in the kidney of doca-salt hypertensive rats. Life Sciences 1995, 58 (1) , PL1-PL7.
    98. Katsuya Fujita, Yasuo Matsumura, Yohko Miyazaki, Masanori Takaoka, Shiro Morimoto. Role of endothelin-1 in hypertension induced by long-term inhibition of nitric oxide synthase. European Journal of Pharmacology 1995, 280 (3) , 311-316.
    99. R.A. Rivero, W.J. Greenlee, P.D. Williams, G.R. Kieczykowski, D.L. Williams. Discovery of substituted 8,9-dicarboxyldibenzo [2,3:5,6] bicyclo [5.2.0] nonan-4-ones with moderate binding affinity to the endothelin ETA and ETB receptors. Bioorganic & Medicinal Chemistry Letters 1995, 5 (13) , 1401-1404.
    100. Volker Breu, Kento Hashido, Clemens Broger, Chikara Miyamoto, Yasuhiro Furuichi, Ashley Hayes, Barbara Kalina, Bernd-Michael LOFfler, Henri Ramuz, Martine Clozel. Separable Binding Sites for the Natural Agonist Endothelin-1 and the Non-Peptide Antagonist Bosentan on Human Endothelin-A Receptors. European Journal of Biochemistry 1995, 231 (1) , 266-270.
    Load all citations